• Luminate meets primary endpoint in phase 2 trial for dry AMD

    1 month ago - By Healio

    A treatment candidate for dry age-related macular degeneration met its primary endpoint in a phase 2 study, with 48% of patients gaining at least eight letters of vision, according to a press release from Allegro Ophthalmics.
    The prospective, randomized, double-masked, placebo-controlled trial evaluated safety and efficacy of Luminate in intermediate dry AMD. Patients in the treatment arm were randomly assigned to receive one 1-mg Luminate intravitreal injection at baseline and a second at week 16, while those in the sham arm received a sham injection at baseline
    Read more ...